Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depressive Disorder NOS Clear all
Active, not recruiting Phase 2 Interventional

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

NCT05947383
View directory record Official record
Conditions
Cancer, Major Depressive Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer-led Group Intervention for Coping With Disaster

NCT03907995
View directory record Official record
Conditions
Anxiety Disorder, PTSD, Depressive Symptoms, Anger, Depressive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators

NCT02809677
View directory record Official record
Conditions
Asthma, Major Depressive Disorder
Interventions
Non-Interventional
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 70 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 22, 2026, 5:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Long-term Observation of Participants With Mood Disorders

NCT04877977
View directory record Official record
Conditions
Depression, Suicide Risk
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 5:02 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:02 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Rescuing the Ruminating Brain: Identifying Biomarkers of Rumination and Mindfulness Through Concurrent EEG and Functional Magnetic Resonance Imaging (fMRI) Studies of Schizophrenia and Depression

NCT03758495
View directory record Official record
Conditions
Schizophrenia, Depressive Disorder, Major
Interventions
Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 22, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal Sleep and Mental Health

NCT06544941
View directory record Official record
Conditions
Postpartum Depression, Postpartum Anxiety, Sleep Disturbance, Infant Behavior, Maternal Behavior, Inflammation, Military Family
Interventions
Smart Bassinet, HALO
Device
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 5:02 PM EDT
Completed No phase listed Observational

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavior Therapy (CBT), Nonspecific Supportive Therapy (PBO)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Therapist-Guided Smartphone-Delivered CBT for MDD

NCT05386329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mindset: Therapist-guided smartphone-delivered CBT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 5:02 PM EDT
Enrolling by invitation Phase 4 Interventional

Precision Care for Major Depressive Disorder

NCT06580041
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
Drug · Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Major Depressive Disorder With Mixed Features - Extension

NCT01423253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

NCT00518986
View directory record Official record
Conditions
Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

NCT04279522
View directory record Official record
Conditions
MDD
Interventions
Relivion®DP- Active, Relivion®DP- Sham
Device
Lead sponsor
Neurolief Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Miami Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Effects of Psilocybin in Major Depressive Disorder

NCT03181529
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

A Study in Depression and Associated Painful Physical Symptoms

NCT01070329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Sherman Oaks, California • Cromwell, Connecticut • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 22, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

NCT07111390
View directory record Official record
Conditions
Depression, MDD, Major Depressive Disorder, Major Depressive Episode
Interventions
60Hz Intermittent Light Therapy, Sham Light Therapy
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
24 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

NCT03861988
View directory record Official record
Conditions
Major Depressive Disorder, Surgery, Orthopedic Disorder
Interventions
Ketamine, Normal saline (placebo)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional

Nutritional Intervention for College Students With Depression

NCT07490782
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Mediterranean Diet, Time-Restricted Eating
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

NCT01942785
View directory record Official record
Conditions
Major Depressive Disorder, Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Tucson, Arizona • Glendale, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Sexual Functioning Study With Antidepressants

NCT00316160
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
45
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Sertraline for the Prevention of Recurrent Postpartum Depression

NCT00276900
View directory record Official record
Conditions
Depression
Interventions
Sertraline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 22, 2026, 5:02 PM EDT